55results about How to "Avoid burst phenomenon" patented technology

The invention provides a calcium alginate-graphene oxide nanofiber and a preparation method and a drug-carrying calcium alginate-graphene oxide nanofiber and relates to the technical field of nanofibers. The preparation method of the calcium alginate-graphene oxide nanofiber comprises the following step: carrying out microfluidics spinning on a mixed solution of calcium alginate and graphene oxideand a calcium chloride solution, thereby obtaining the calcium alginate-graphene oxide nanofiber. The technical problem that a sudden drug release phenomenon is caused as a conventional calcium alginate nanofiber is good in hygroscopicity and low in mechanical strength is alleviated. By adopting the preparation method provided by the invention, the graphene oxide is put into raw materials, so that the calcium alginate-graphene oxide nanofiber has hydrogen bond interactions with oxygen-containing groups on a graphene oxide sheet and hydroxyl in calcium alginate molecules, the hydrogen bond function of the calcium alginate and water molecules is weakened, the swelling velocity of the calcium alginate is reduced, and the sudden drug release phenomenon can be prevented.

The present invention relates to a method of preparing BCNU which has the biodegradation high polymer ultra-thin fiber form. Dissolve the BCNU into the solution of high polymer which can be biodegraded, electrospinning, so non-woven fabrics or felt of ultra-thin fiber wrapped with BCNU. The preparation is simple and cheap, the diameter of drug loading fiber can be controlled at the dimension of 0.2 - 2 ª–m, drug loading can be controlled at the range of 0.1 - 100%. The release of drug is study. It has high speed of drug releasing and can also release BCNU steadily for a long time. The fiber itself can biodegrades completely so it has little poisonous side effect. On the other hand, because BCNU is wrapped in the fiber and released slowly, so it conquers the disadvantage of short half-life, and also reduces its poisonous side effect. This trademark is suitable for part chemotherapy after the operation of tumour.

The invention relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and belongs to the technical field of medicine. The metformin hydrochloride sustained-release tablet is composed of sustained-release granules, sustained-release microcapsules and a lubricant, and is prepared through tabletting, wherein the weight ratio of the metformin hydrochloride in the sustained-release granules and the metformin hydrochloride in the sustained-release microcapsules is (3:7)-(6:4), and the lubricant is selected from superfine silica powder or magnesium stearate. According to the preparation method, a traditional spray drying method is improved, by combining a dry granulation process, the sustained-release microcapsules and sustained-release granules of different processes are prepared, tabletting is further carried out to prepare the metformin hydrochloride sustained-release tablet, the specific ratio of the sustained-release microcapsules prepared by the spray drying process to the sustained-release granules prepared by the dry granulation process is explored, and the metformin hydrochloride sustained-release tablet of which the inner portion has the structure of the sustained-release microcapsules and the sustained-release granules is finally obtained. The metformin hydrochloride sustained-release tablet and the preparation method thereof achievea good release behavior of the sustained-release tablet, overcome the shortcomings of sudden release and incomplete release, obtain a better release curve, and also greatly reduce the impurity content.

The invention belongs to the technical field of pharmaceutical chemicals and discloses segmented copolymer - docetaxel combination, a preparation thereof and a preparation method thereof. The combination is combined by bonding polyoxyethylene - polypropylene oxide - polyoxyethylene (PEO- b - PPO - b - PEO with a product name as Pluronics (BASF company)) triblock copolymer and docetaxel through ester bond, and the Pluronics - docetaxel combination is obtained. By utilizing amphipathy of the combination and adopting physical methods to prepare micelle aqueous solution, a freeze-dried preparation can also be prepared. Nanomicelle is capable of gathering at tumor parts through 'enhanced permeation and retention effects (EPR effects)', and tumor targeting of docetaxel is enhanced. Besides, an active targeting factor is connected on Pluronics polymer so as to have the function of active targeting. The segmented copolymer - docetaxel combination overcomes the defects that existing docetaxel injection is poor in water-solubility and severe in allergic reaction and the like.

The invention relates to an antibacterial microcapsule with clove oil embedded in a laurinol modified alginic acid derivative and a preparation method of the antibacterial microcapsule, and belongs to the technical field of modification of high polymer materials. The antibacterial microcapsule comprises sodium alginate, laurinol and clove oil.The preparation method comprises the following steps that firstly laurinol is used to modify sodium alginate to obtain sodium alginate graft-copolymerized laurinol SA-Da, and then the clove oil is embedded to obtain the antibacterial microcapsule with the clove oil embedded in the laurinol modified alginic acid derivative. The prepared slow-release antibacterial microcapsule is relatively high in antibacterial property, can effectively inhibit the growth and propagation of microorganisms, has a certain slow release effect, slowly releases the antibacterial ingredient of the clove oil along with the change of time, has an excellent slow-release antibacterial effect, and can be applied to a food packaging film to prolong the food shelf-life and improve the food quality, and therefore, the antibacterial microcapsule has an excellent market prospect.

The invention discloses a polypeptide sustained-release microsphere preparation. The preparation is composed of 3% to 10% by weight of exenatide or its salt as a raw material and 90% to 97% by weight of a polymer as an auxiliary material. An in-vitro initial release rate of the sustained-release microsphere preparation in 1h is less than 2%. The invention also provides a method for preparing the polypeptide sustained-release microsphere by an O/O phase coacervation method. The polypeptide sustained-release microsphere preparation has low microsphere sizes, low burst release and high entrapment efficiency, further prolongs long drug release time, can continuously release drugs for half a month or more in single-dose administration, can release drugs for 3 months, significantly reduces the frequency of administration, improves the patient's compliance, overcomes the defect of the existing peptide sustained-release microsphere preparation platform period and can get a near-zero order release curve.

The invention relates to a chitosan-carboxylated chitosan nanosphere loading an insoluble antitumor drug. The nanosphere has a porous and aperture-controlled structure which controls rapid and stable release of the drug. Polyethylene glycol (PEG) chains and tumor-targeting specific molecules are coupled on the surface of the nanosphere, so as to effectively increase the cycle period of the drug in vivo, improve the affinity of the nanosphere to tumor cells and improve the bioavailability of the drug. Besides, the nanosphere has less toxic side effects and better antitumor effects. The invention also provides a method for preparing the chitosan-carboxylated chitosan nanosphere loading or combining the insoluble antitumor drug. The amino groups of chitosan/carboxylated chitosan are cross-linked to form a sphere, and the carboxyl groups of carboxylated chitosan are coupled with the PEG chains and then grafted with the targeting molecules, so that the drug is uniformly dispersed in the form of in-situ crystallization in chitosan and its derivative nanosphere, as a result, the drug-loading rate is greatly increased and the release rate of the drug is stabilized.

The invention discloses a sustained-release tablet containing trazodone hydrochloride and a preparation method of the sustained-release tablet. The sustained-release tablet is prepared from, in percentage by weight of the whole tablet, 15%-65% of trazodone hydrochloride, 30%-85% of a sustained-release framework and 0.1%-10% of other medical auxiliaries, wherein the sustained-release framework is prepared from high-viscosity hydroxypropyl methylcellulose and water-soluble filler in the weight ratio being 1: (0.3-1.2), and other medical auxiliaries comprise a flow aid and a lubricating agent. Through matched use of high-viscosity hydroxypropyl methylcellulose and the water-soluble filler, the microporous sustained-release framework is formed; the prepared sustained-release tablet containing trazodone hydrochloride can effectively control the release speed of trazodone hydrochloride and can completely release trazodone hydrochloride contained in a sustained release tablet core within certain time, so that water-soluble trazodone hydrochloride is easily stabilized and effectively released, plasma concentration is prevented from fluctuating substantially, the prescription is simple, and the process is simple and convenient.

The invention belongs to the field of pharmaceutical preparations, specially relates to a preparation method of a controlled-release drug, and particularly relates to theophylline and nifedipine controlled-release tablets prepared by using the method. The controlled-release drug is prepared by adopting combination of two techniques of hot melt extrusion and membrane controlling. Compared with the prior art, the method disclosed by the invention has the advantages that the drug is subjected to melting and solidification based on that the drug is preferably controlled to release at a zero level, the quality is uniform, and the phenomenon that burst release of other drugs in controlled-release dosage forms possibly occurs is avoided; for drugs with narrow therapeutic windows, clinical application is safer; organic solvents are not used, so that the security of mass production is good.

A slowly-releasing micropill containing indapamide as its active component is composed of pill core, quick-releasing layer and slow-releasing layer. It is prepared through proportionally mixing filler, adhesive and lubricant, granulating to become (10-30)-mesh pill cores, dissolving indapamide and high-molecular adhesive in solvent, spraying it on the surface of pill cores, dissolving the retarder, pore-forming agent and plasticizer of antisticking agent in solvent, and spraying it on the surface micropill. Its advantages are high slow releasing effect within 24 hr and no sudden release.

The invention relates to a preparation method of a nano-particle loaded with two anti-hepatoma medicines and provided with a two-layer controlled release-light heat-target function. The method includes the steps: modifying carboxymethyl Pulullan on carboxymethyl chitosan by taking hydrophilic polyacrylamide as a bridge, and enabling the carboxymethyl chitosan to have a target function when the hydrophilcity of the carboxymethyl chitosan is improved; loading doxorubicin serving as an anti-cancer drug on polydopamine, wrapping the doxorubicin with hydrophilic polyvinylpyrrolidone and Arabic gum,loading Sorafenib serving as an anti-cancer drug on the outer surface of an oil phase of the hydrophilic polyvinylpyrrolidone and the Arabic gum, and wrapping a system with carboxymethyl chitosan-polyacrylamide-carboxymethyl Pulullan nano-particle water solution to obtain the nano-particle loaded the two anti-hepatoma medicines and provided with the two-layer controlled release-light heat-targetfunction. The polymer nano-particle can control release of the two-layer anti-hepatoma medicines and is combined with a light heat performance of the polydopamine to treat a liver cancer.

The invention belongs to the technical field of medicines and particularly relates to a nifedipine sustained-release tablet and a production process thereof. The provided nifedipine sustained-releasetablet is prepared from components in parts by mass as follows: 20 parts of nifedipine, 13-20 parts of a sustained-release agent, 3-5 parts of a retardant, 72-76 parts of a filling agent, 1-2 parts ofa disintegrating agent, 0.3-0.7 part of a fluidizer and 0.5-1 part of a lubricant. The provided nifedipine sustained-release tablet is stable in drug release, can guarantee full release within 24 hours and maintain necessary blood-drug concentration and avoids the sudden release phenomenon. Besides, the prepared nifedipine sustained-release tablet is uniform in drug dispersion.

The present invention provides a lansoprazole sustained-release preparation, which is characterized in that a sustained-release preparation prescription consists of a core prescription and a coating layer prescription. The core prescription consists of lansoprazole, lactose, hydroxypropyl methylcellulose, cross-povidone, powdered steatile, and magnesium stearate. The coating layer prescription isa mixture of two or more of ethyl cellulose, hydroxypropyl methylcellulose, polyacrylic resin, microcrystalline cellulose, and magnesium stearate. The preparation of lansoprazole sustained-release tablets by a compression coating method can better avoid the sudden release of the drug, and the prescription is simple, and separated addition of a pore forming agent and other sustained-release materials is not required. The invention provides the preparation method of lansoprazole sustained-release tablets with slow release in the intestine and high stability, is suitable for industrial production, and improves patient compliance, medication safety and bioavailability.

The invention relates to injectable artificial dermis for promoting wound healing as well as a preparation method and application of the injectable artificial dermis. The injectable artificial dermis for promoting wound healing comprises collagen-polysaccharide composite hydrogel microspheres loaded with polyphosphate. The microstructure of the hydrogel microsphere is composed of a cross-linked polymer network, the hydrogel microsphere has high permeability, internal and external circulation of nutrient substances and substance exchange of metabolites are facilitated, and meanwhile, the hydrogel microsphere serves as an injectable stent to support cell ingrowth and induce cell proliferation and differentiation; due to the small size, the materials can be injected to a specific part, and the high viscosity after injection can be guaranteed; and aiming at a wound surface with irregular depth and a cavity, the dressing has good effects of filling and covering and promoting repair of tissues in a lacuna. Meanwhile, the loaded amorphous polyphosphate is hydrolyzed under the action of alkaline phosphatase, chemical energy is released, energy needed for wound healing is provided, cell proliferation, growth and migration are promoted, and formation of a vascular network is accelerated.